The Pharma Letter

Protara Therapeutics updates on TARA-002 development

New York-based clinical-stage cancer and rare diseases drug developer Protara Therapeutics today announced that the US Food ...

Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations

Receiving these important FDA designations and invitation to participate in the CDRP program highlights the significant unmet need among pediatric patients with LMs and underscores our belief that ...
Hosted on MSN

enGene Shares Rise After FDA Taps Bladder Cancer Therapy for CMC Pilot

enGene Holdings Inc. (NASDAQ:ENGN) traded 2% higher on Tuesday after the company revealed that the FDA has selected its bladder cancer therapy for a specialized program aimed at accelerating ...
Seeking Alpha

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia

Breakthrough Therapy designation based on interim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures LX2006 also selected for ...
Observer

The Economics of Drug Development: What it Will Really Take to Reduce Drug Prices

As drug costs rise and public trust falls, A.I. may transform the economics of clinical trials—and reshape the future of pharma. Unsplash+ Sixty percent of the total U.S. population takes at least one ...
Morningstar

Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...